One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Healthcare ➤ Osteoporosis Drugs Market
Osteoporosis Drugs Market
Osteoporosis Drugs Market
Published date: Oct 2024 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Healthcare ➤ Osteoporosis Drugs Market

Osteoporosis Drug Market By Drug Class (Bisphosphonates, Parathyroid Hormone Therapy Drugs), By Route Administration (Oral and injectable), and By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

  • Published date: Oct 2024
  • Report ID: 22087
  • Number of Pages: 232
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • Drug Class Analysis
    • Distribution Analysis
    • Route Administration
    • Key Market Segments
    • Driver
    • Restraint
    • Opportunity
    • Trend
    • Regional Analysis
    • Key Players Analysis
    • Recent Development
    • Report Scope

    Report Overview

    Osteoporosis Drugs Market size is expected to be worth around USD 9.8 Billion by 2032 from USD 7 Billion in 2022, growing at a CAGR of 3.5% during the forecast period from 2023 to 2032.

    A medical condition known as osteoporosis is identified by small bone density, which affects the bones and makes them more porous, making them more vulnerable to fractures. Overproduction of the hormone known as parathyroid results in osteoporosis condition. The condition can result in implacable fractures, which can be harmful to the patient’s health.

    As a result, treatment, including osteoporosis medications, is necessary, such as Bisphosphonates, selective estrogen inhibitors modulator, parathyroid hormone therapy, calcitonin, and RANK ligand inhibitors of the drugs on the market, which are used to treat osteoporosis condition. These medications can be administrated into the body in a variety of ways.

    Osteoporosis Drugs Market Value

    Key Takeaways

    • The global osteoporosis drugs market size is expected to reach USD 9.8 Bn by 2032 from USD 7.0 Bn in 2022, growing at a CAGR of 3.5% during the forecast period.
    • The Bisphosphonates segment dominated the market growth during the forecast period.
    • The rank ligand inhibitors market is anticipated to expand at the fastest rate during the forecast period.
    • The oral route of administration dominates the global osteoporosis market.
    • The hospital pharmacies segment is expected to grow at a faster rate during the forecast period.
    • Increasing healthcare expenditure is a major driver of the osteoporosis drug market.
    • The market’s expansion is being hampered by the adverse effects of anti-inflammatory medications.
    • The osteoporosis drug industry is also growing because of the expanding healthcare sectors in a number of emerging economies.
    • New and effective diagnostic methods for screening for osteoporosis have emerged as a result of advancements in technology.
    • Injectable osteoporosis medications are anticipated to experience faster growth during the forecast period.
    • COVID-19 has disturbed or delayed many osteoporosis patients’ treatment.
    • North America region dominates the largest shares in the market.

    Drug Class Analysis

    The Bisphosphonates Segment Dominated the Market Growth During the Forecast Period. The global osteoporosis Drug market is segmented into various drug classes that made the market growth such as bisphosphonates, selective estrogen inhibitors, modulators, parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Bisphosphonates accounted for the majority of shares in the osteoporosis drugs market as a result, major players increased investments in research and development of innovative novel bisphosphonates.

    The market expansion is also driven by the widespread use of bisphosphonates to treat osteoporosis. The rank ligand inhibitors market is anticipated to expand at the fastest rate during the forecast period due to their use to manage bone transformation by acting as a chemoattractant to the bone for tumor cells that accelerate their RANK receptor.

    The RANK ligand inhibitor category is anticipated to expand at the highest CAGR over the forecast period. Osteoporosis is treated with rank ligand inhibitors in patients at risk of fracture. The rising the growth development of rank ligand inhibitors is assisted by favorable patient outcomes. Positive patient outcomes can be authorized to fundamental changes in bone metabolism. Rank ligand inhibitors can be combined with other medications to produce a synergistic effect across the complete treatment plan.

    Distribution Analysis

    An increased Number of Patient Visits in Hospitals for Osteoporosis Treatment Drives the Hospital Pharmacies Segment. The market is segmented into hospitals pharmacies, retail pharmacies, and online pharmacies according to the distribution channel.

    Increased in the number of osteoporosis patients demanding treatment in hospitals. Support from the government for the development of hospital pharmacies and other factors that fuel their growth.

    Route Administration

    On the basis of the route of administration, the osteoporosis drug is segmented into oral and injectable drugs. Due to the rise in oral drug use, the oral route of administration dominates the market. In addition, the rise in oral medication use is having a positive impact on larger production, which has contributed to the market’s expansion over time.

    In contrast, it is anticipated that the injectable route of administration segment will experience faster growth during the forecast period due to the introduction of a new biosimilar that is safer and more user-friendly for osteoporosis treatment.

    Osteoporosis Drugs Market

    Key Market Segments

    By Product

    • Bisphosphonates
    • Parathyroid Hormone Therapy Drugs
    • Calcitonin
    • Selective Estrogen Receptor Modulators
    • RANK Ligand Inhibitor
    • Others

    By Route of Administration

    • Oral
    • Injectable

    By Distribution Channel

    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Sales

    Driver

    Increasing Healthcare Expenditure

    Rising healthcare costs globally, spurred by increasing disease prevalence and enhanced healthcare infrastructure, make treatments more accessible and affordable. This has led to improved market penetration and the introduction of innovative products targeting women’s health, further driving market growth.

    Restraint

    Adverse Effects and Increased Risk of Osteoporosis Drugs

    The growth of the osteoporosis drug market is constrained by the adverse effects associated with anti-inflammatory and osteoporosis medications, including severe side effects like hot flashes, leg cramps, vomiting, and diarrhea. Additionally, patent expirations and increasing risk factors further hinder market expansion.

    Opportunity

    Expanding Healthcare Sectors in Emerging Economies

    The osteoporosis drug market benefits from growing healthcare expenditures in emerging economies such as China, India, Brazil, and South Africa, coupled with an aging population and increased public health awareness. Investments in healthcare infrastructure by governments in these regions provide significant opportunities for market expansion through regional growth and new product developments.

    Trend

    Dominance of Injectable Osteoporosis Drugs

    Technological advancements in diagnostics have improved osteoporosis screening, increasing the diagnosed patient pool and treatment rates. Injectable drugs, favored for their ease of administration and lower gastrointestinal impact, are expected to dominate the market, particularly benefiting patients unable to take oral bisphosphonates due to conditions like impaired kidney function.

    Regional Analysis

    North America Region accounts for Largest Share During Forecast Period

    In North America, the osteoporosis drugs market dominates the largest shares in the market. This is because the number of elderly people, obesity, lifestyle-related diseases, and osteoporosis are all rising in the region. For instance, approximately 10 million people in the United States have osteoporosis, and 34 million people in the United States have low bone density, which increases their risk of fracture due to rising awareness of osteoporosis treatment, and changing lifestyles.

    High healthcare costs and drug use for osteoporosis are common in North America. The growing population, shifting lifestyles, rapid urbanization, and rising awareness are all contributing factors to the expansion of the osteoporosis care market in Europe. Compared to hypertension and rheumatoid arthritis, osteoporotic fractures account for slightly more disability-adjusted life years in Europe.

    Osteoporosis Drugs Market Region

    Key Regions

    • North America
      • The US
      • Canada
      • Mexico
    • Eastern Europe
      • Russia
      • Poland
      • The Czech Republic
      • Greece
      • Rest of Eastern Europe
    • Western Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Portugal
      • Ireland
      • Austria
      • Switzerland
      • Benelux
      • Nordic
      • Rest of Western Europe
    • APAC
      • China
      • Japan
      • South Korea
      • India
      • Australia & New Zealand
      • Indonesia
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Colombia
      • Chile
      • Argentina
      • Costa Rica
      • Rest of Latin America
    • Middle East & Africa
      • Algeria
      • Egypt
      • Israel
      • Kuwait
      • Nigeria
      • Saudi Arabia
      • South Africa
      • Turkey
      • United Arab Emirates
      • Rest of MEA

    Key Players Analysis

    There are a number of major players in the osteoporosis medication market, which is comparatively determined by Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Novartis International AG, and Actavis PLC are among the market leaders at the moment.

    Due to the growing combination of common strategies by key players to maintain their competitive position, this industry is anticipated to experience intense competition during the forecast period. High R&D expenditures, unions and achievements, and contracts for drug advancements are additional strategies incorporated.

    With the presence of many local and regional players, the market for companion diagnostics is fragmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches. The following are some of the major players in the global osteoporosis drug Market.

    Market Key Players

    • Amgen Inc.
    • Eli Lilly and Company
    • Hoffmann-La Roche AG
    • Mark and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Radius Health Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novo Nordisk A\S
    • UCB
    • Other key players

    Recent Development

    • In October 2024: Eli Lilly announced a major investment of $4.5 billion in a new facility named the Lilly Medicine Foundry, aimed at driving innovation in drug production, including medications for osteoporosis. This new complex is part of a broader expansion in Indiana, which also includes significant investments in manufacturing capabilities that contribute to the production of various therapies, potentially encompassing osteoporosis treatments​.
    • In December 2023: Pfizer completed the acquisition of Seagen Inc., significantly enhancing its oncology pipeline which includes multiple modalities potentially applicable to osteoporosis through novel biologic combinations. This acquisition, valued at $229 per share for all outstanding common stock, reflects a strategic expansion aimed at developing transformative cancer and potentially osteoporosis treatments.

    Report Scope

    Report Features Description
    Market Value (2022) USD 7.0 Bn
    Forecast Revenue (2032) USD 9.8 Bn
    CAGR (2023-2032) 3.5%
    Base Year for Estimation 2022
    Historic Period 2016-2022
    Forecast Period 2023-2032
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered By Type (Bisphosphonates, Parathyroid Hormone Therapy Drugs, Calcitonin, Selective Estrogen Receptor Modulators, RANK Ligand Inhibitor and Others); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Sales); Route Administration (Oral and Injectable)
    Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Mark and Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A\S, UCB, Other key players
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three license to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
    Osteoporosis Drugs Market
    Osteoporosis Drugs Market
    Published date: Oct 2024
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Amgen Inc.
    • Eli Lilly and Company
    • Hoffmann-La Roche AG
    • Mark and Co. Inc.
    • Novartis AG Company Profile
    • Pfizer Inc Company Profile
    • Radius Health Inc.
    • Teva Pharmaceutical Industries Ltd. Company Profile
    • Novo Nordisk A\S
    • UCB
    • Other key players
  • settingsSettings

Related Reports

  • Bone Replacement Market
  • Bone Growth Stimulator Market
  • Bone Graft Substitutes Market
  • Orthopedic Navigation Systems Market
  • Pediatric Orthopedic Implant Market
  • Wrist Replacement Orthopedic Devices Market
  • Orthopedic Implants Market

Our Clients

  • Our Clients
Inquiry Before Buying

Osteoporosis Drugs Market
  • 22087
  • Oct 2024
    • ★★★★★
      ★★★★★
    • (103)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.